2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a
![]() | |
Names | |
---|---|
Other names Photochlor | |
Identifiers | |
3D model (JSmol) | |
Abbreviations | HPPH |
ChemSpider | |
PubChem CID | |
UNII | |
| |
| |
Properties | |
C39H48N4O4 | |
Molar mass | 636.837 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH) is a photosensitiser chemical that is used in photodynamic therapy.[1]
It is being developed under the brand name Photochlor.
Clinical trials
[edit]A phase I/II clinical trial started in 1997 for esophageal cancer.[2]
A phase II trial for non-small cell lung cancer is due to run from 2007 to 2011.[3]
References
[edit]- ^ Lobel, J; MacDonald, IJ; Ciesielski, MJ; Barone, T; Potter, WR; Pollina, J; Plunkett, RJ; Fenstermaker, RA; Dougherty, TJ (2001). "2-1-hexyloxyethyl-2-devinyl pyropheophorbide-a (HPPH) in a nude rat glioma model: implications for photodynamic therapy". Lasers in Surgery and Medicine. 29 (5): 397–405. doi:10.1002/lsm.10001. PMID 11891727. S2CID 22578518.
- ^ Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors
- ^ Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages
External links
[edit]